氟替卡松

氟替卡松
臨床資料
AHFS/Drugs.com	Monograph
懷孕分級	C(鼻腔內吸入);
給藥途徑	鼻腔內吸入，局部塗搽
ATC碼	D07AC17 (WHO) R01AD08 R03BA05;
法律規範狀態
法律規範	英：處方藥（℞-only） (POM); 美：處方藥（℞-only）;
藥物動力學數據
生物利用度	0.51% (鼻腔內)
血漿蛋白結合率	91%
藥物代謝	鼻腔內; 肝臟(CYP3A4-中介)
生物半衰期	10小時
排泄途徑	腎臟
識別資訊
	IUPAC命名法 S-(fluoromethyl) (6S,8S,9R,10S,11S,13S,14S,16R,17R)-; 6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-; 6,7,8,11,12,14,15,16-octahydrocyclopenta[a]; phenanthrene-17-carbothioate; ;
CAS號	80474-14-2（（丙酸酯）） ; 90566-53-3
PubChem CID	5311101;
DrugBank	DB00588 ;
ChemSpider	4470631 ;
UNII	CUT2W21N7U;
KEGG	D07981 ;
ChEBI	CHEBI:5134 ;
ChEMBL	ChEMBL1201396 ;
CompTox Dashboard（英語：CompTox Chemicals Dashboard） (EPA)	DTXSID0044022 ;
化學資訊
化學式	C22H27F3O4S
摩爾質量	444.508 g/mol
3D模型（JSmol（英語：JSmol））	交互式圖像;
	SMILES O=C(SCF)[C@]3(O)[C@]2(C[C@H](O)[C@]4(F)[C@@]/1(\C(=C/C(=O)\C=C\1)[C@@H](F)C[C@H]4[C@@H]2C[C@H]3C)C)C;
	InChI InChI=1S/C22H27F3O4S/c1-11-6-13-14-8-16(24)15-7-12(26)4-5-19(15,2)21(14,25)17(27)9-20(13,3)22(11,29)18(28)30-10-23/h4-5,7,11,13-14,16-17,27,29H,6,8-10H2,1-3H3/t11-,13+,14+,16+,17+,19+,20+,21+,22+/m1/s1 ; Key:MGNNYOODZCAHBA-GQKYHHCASA-N ;

氟替卡松（英語：fluticasone）為一種綜合的糖皮質激素。^[1]

與糠酸酯（furoate）或丙酸酯（propanoate)的合成品可以用為局部抗炎性、比如鼻炎方面：^[2]

參見

^ Briggs, Gerald G.; Freeman, Roger K.; Yaffe, Sumner J., Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk, Lippincott Williams & Wilkins: 600, 2012 [2013-10-28], ISBN 1451153597, （原始內容存檔於2014-01-01）.
^ Spratto, George R.; Woods, Adrienne L., Delmar Nurse's Drug Handbook 2012, Cengage Learning: 748, 2012 [2013-10-28], ISBN 1111310653, （原始內容存檔於2014-01-01）.

Jarvis B., Faulds D. (1999): Inhaled fluticasone propionate: A review of its therapeutic efficacy at dosages < or = 500 microg/day in adults and adolescents with mild to moderate asthma. Drugs, 57(5), 769–803. PMID 10353302
Johnson M. (1995): The anti-inflammatory profile of fluticasone propionate. Allergy, 50(23), 11–14. PMID 7604948
Keating G.M., McCormack P.L. (2007): Salmeterol/fluticasone propionate: a review of its use in the treatment of chronic obstructive pulmonary disease. Drugs, 67(16), 2383–2405. PMID 17983257
Reynolds N.A., Lyseng-Williamson K.A., Wiseman L.R. (2005): Inhaled salmeterol/fluticasone propionate: a review of its use in asthma. Drugs, 65(12), 1715–1734. PMID 16060707
Spencer C.M., Jarvis B. (1999): Salmeterol/fluticasone propionate combination. Drugs, 57(6), 933–940. PMID 10400406
Staresinic A.G., Sorkness C.A. (2000): Fluticasone propionate: A potent inhaled corticosteroid for the treatment of asthma. Expert Opin Pharmacother, 1(6), 1227-1244. PMID 11249490
Avamys, Zusammenfasuung der Merkmale des Arzneimittels (PDF; 440 kB), Stand Dezember 2012, Europäische Arzneimittelagentur.